// App-Quantinova.ai

: IgD Multiple Myeloma, Does It Still Have a Poor Prognosis?

Researchers

Presenter

  • Abhishek Singh

Principal Investigators

  • Anusha Chidharla

  • Nidhi Jain

  • Neha Debnath

  • Inshiya Dawoodi

  • Geetika Kukreja

Medical Centers

  • INTERNAL MEDICINE, SAINT VINCENT HOSPITAL, Worcester, MA

  • Hematology/Oncology, Kansas University Medical Center, Kansas City, KS

  • Internal Medicine, Hackensack Meridian Health Palisades Medical Center, New Jersey, NJ

  • Division of Hematology-Oncology, Department of Internal Medicine, Henry Ford Hospital, Clinton

  • Internal Medicine, Icahn School of Medicine at Mount Sinai Morningside/West, New York

  • Griffin hospital, Derby, CT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Peripheral Nervous System

  • Endocrine/metabolic Diseases (ME)

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Monoclonal gammopathy

  • Multiple Myeloma

  • Peripheral neuropathy

  • Gastroesophageal reflux disease

Biomarkers

  • Syndecan-1

  • Tumor protein p53

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • daratumumab Intravenous

  • Bortezomib

  • Selinexor

  • Lanthanum carbonate

  • Epimorph

  • TP53

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved